Products for Research Use Only

Miglustat

CAT: 0804-HY-17020-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17020-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease[1].
CAS Number
72599-27-0
Product Name Alternative
N-Butyldeoxynojirimycin; NB-DNJ; OGT 918
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Glucosylceramide Synthase (GCS)
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/miglustat.html
Purity
99.86
Solubility
H2O : 250 mg/mL (ultrasonic)
Smiles
O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O
Molecular Formula
C10H21NO4
Molecular Weight
219.28
Precautions
H315, H319, H335
References & Citations
[1]Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7 (6) :555-65. |[2]G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Cell Rep. 2022 Jul 5;40 (1) :111049.|Front Pharmacol. 2023 Jun 26:14:1191692. |J Virol. 2025 Mar 18;99 (3) :e0001825.|Nat Commun. 2024 Aug 14;15 (1) :6970.|Preprints. 2023 Dec 20.|Cell. 2019 Dec 12;179 (7) :1483-1498.e22.

Popular Products